PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30190369-2	2019	The phase III SHARP trial showed a median time-to-progression (mTTP) of 5.5 months, overall response rate (ORR) of 2%, and median overall survival (mOS) of 10.7 months with sorafenib.	Sorafenib	173-182	Moloney sarcoma oncogene	Mus musculus	148-151	
30190369-13	2019	Shorter TTP and OS were associated with increases in Tregs and CD56Dim natural killer (NK) cells after sorafenib alone and plasma sMET after combination treatment (all P < 0.05).	Sorafenib	103-112	Moloney sarcoma oncogene	Mus musculus	16-18	
31799203-12	2019	Conclusion: When comparing 2 periods of treatment in advanced HCC patients under sorafenib, duration of treatment and mOS were higher in the recent period.	Sorafenib	81-90	Moloney sarcoma oncogene	Mus musculus	118-121	
26441378-2	2016	We investigated the effect of post-progression survival (PPS) and progression-free survival (PFS) on overall survival (OS) in patients whose advanced HCC was treated by sorafenib.	Sorafenib	169-178	Moloney sarcoma oncogene	Mus musculus	119-121	
27299940-4	2016	The mOS increased 21% when the AAT was sorafenib (SOR) or 42% when locoregional therapy was coadministered.	Sorafenib	39-48	Moloney sarcoma oncogene	Mus musculus	4-7	
27299940-4	2016	The mOS increased 21% when the AAT was sorafenib (SOR) or 42% when locoregional therapy was coadministered.	Sorafenib	50-53	Moloney sarcoma oncogene	Mus musculus	4-7	
30395717-2	2018	In 2007, sorafenib became the first Food and Drug Administration (FDA) approved first line systemic treatment for HCC, however, it confers only modest benefit in median overall survival (mOS) and comes with significant side effects.	Sorafenib	9-18	Moloney sarcoma oncogene	Mus musculus	187-190	
34000725-11	2021	mOS from 1st-line therapy with tyrosine kinase inhibitor plus sorafenib-regorafenib-lenvatinib was 29.5 months; that with lenvatinib-sorafenib-regorafenib was not obtained.	Sorafenib	62-71	Moloney sarcoma oncogene	Mus musculus	0-3